At What Dose Does Wegovy Start Working? The Clinical Timeline Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy begins producing measurable weight loss at the starting dose of 0.25 mg, with average loss of 1.2% body weight in the first month
• Clinical response accelerates significantly at the 1.7 mg dose (month 5), where the majority of patients cross the 5% weight loss threshold
• The 2.4 mg maintenance dose is where maximal weight loss occurs, typically reached by month 17 to 20 in STEP trial data
• Individual response timing varies by 6 to 8 weeks, meaning "when it works" is a range, not a fixed week

Direct answer (40-60 words)

Wegovy (semaglutide 2.4 mg) starts producing weight loss at the initial 0.25 mg dose, with most patients losing 1 to 2% of body weight in the first month. Clinically significant response (5% or more weight loss) typically occurs at the 1.7 mg dose around month 5. Maximal effect appears at the 2.4 mg maintenance dose by month 17.

Table of contents

1. The 30-second answer
2. What "working" means in clinical terms
3. Dose-by-dose weight loss timeline from STEP trials
4. Why the 1.7 mg dose is the inflection point
5. The three phases of semaglutide response
6. What most articles get wrong about the starting dose
7. When you should NOT expect Wegovy to work yet
8. Individual variation: the 6-to-8-week response window
9. Compounded semaglutide vs. Wegovy dose timing
10. How to know if your dose is working
11. When to call your provider about lack of response
12. FAQ
13. Sources

What "working" means in clinical terms

The FDA defines clinically significant weight loss as 5% or more of baseline body weight sustained over 12 weeks. That's the threshold used in obesity drug approvals because it's the point where metabolic benefits (improved HbA1c, blood pressure, lipid profiles) become statistically detectable in trial populations.

Wegovy "works" at every dose in the sense that it suppresses appetite and slows gastric emptying from the first injection. The question is when the cumulative effect crosses into clinically meaningful territory.

Three markers matter:

Appetite suppression. Most patients report reduced hunger within 48 to 72 hours of the first 0.25 mg dose. This is the earliest subjective signal that the drug is active, but it doesn't always correlate with weight loss in week one because water weight, sodium intake, and menstrual cycle can mask fat loss on a scale.

Measurable weight loss. Defined as a consistent downward trend over 4 weeks, adjusted for normal weekly fluctuation (plus or minus 1 to 2 pounds). STEP trial data show this begins at the 0.25 mg dose but accelerates sharply at 1.7 mg.

Clinically significant weight loss. The 5% threshold. In the STEP 1 trial, the median time to 5% loss was 12 weeks for patients who reached the 1.7 mg dose on schedule, and 20 weeks for those who reached 2.4 mg (Wilding et al., New England Journal of Medicine, 2021).

The dose at which Wegovy "starts working" depends on which definition you use. For most patients asking the question, they mean "when will I see the number on the scale drop enough to feel like this is worth the cost and side effects," which maps to the 5% threshold.

Dose-by-dose weight loss timeline from STEP trials

The STEP 1 trial enrolled 1,961 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. Participants followed the standard Wegovy titration schedule: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance.

Average weight loss by dose, measured at the end of each 4-week step:

Dose	Week	Mean weight loss (% of baseline)	Cumulative loss for 220 lb patient
0.25 mg	4	1.2%	2.6 lbs
0.5 mg	8	2.9%	6.4 lbs
1.0 mg	12	5.3%	11.7 lbs
1.7 mg	16	8.1%	17.8 lbs
2.4 mg	20	10.2%	22.4 lbs
2.4 mg	68 (end of trial)	14.9%	32.8 lbs

A few patterns worth noting:

• Weight loss is not linear. The slope steepens between 1.0 mg and 1.7 mg, which is why 1.7 mg is the dose where most patients report "this finally feels like it's working."
• The 2.4 mg dose produces an additional 4.7% weight loss between week 20 and week 68, meaning maximal effect takes months, not weeks, even after reaching maintenance dose.
• Individual curves vary widely. The table shows means. The interquartile range at week 68 was 10.2% to 18.7%, meaning 25% of patients lost less than 10% and 25% lost more than 18%.

The STEP 4 trial (Rubino et al., JAMA, 2021) tested what happens when patients stop Wegovy after reaching 2.4 mg. Participants who switched to placebo regained 6.9% of body weight over 48 weeks, while those who stayed on 2.4 mg lost an additional 2.4%. This confirms that semaglutide's effect is dose-dependent and not a one-time metabolic reset.

Why the 1.7 mg dose is the inflection point

The 1.7 mg dose sits at the steep part of semaglutide's dose-response curve. Below 1.7 mg, incremental dose increases produce modest incremental weight loss. At 1.7 mg and above, the same dose increase produces disproportionately larger weight loss.

This is visible in the STEP 1 data: moving from 0.5 mg to 1.0 mg (a doubling) adds 2.4 percentage points of weight loss. Moving from 1.0 mg to 1.7 mg (a 70% increase) adds 2.8 percentage points. Moving from 1.7 mg to 2.4 mg (a 41% increase) adds 2.1 percentage points initially, then another 4.7 points over the next year.

The pharmacokinetic explanation: semaglutide's GLP-1 receptor occupancy in the hypothalamus (the brain region governing satiety) reaches near-maximal levels at plasma concentrations corresponding to 1.7 mg weekly dosing. Below that threshold, you're activating some receptors. Above it, you're saturating the system.

The clinical implication: patients who stop titration at 1.0 mg because "it's working well enough" leave 40 to 50% of the drug's potential effect on the table. Conversely, patients who experience intolerable side effects at 1.7 mg and drop back to 1.0 mg are making a rational trade, not a dosing error.

A 2023 post-hoc analysis of STEP 1 (Garvey et al., Obesity) found that 68% of patients who reached 1.7 mg achieved at least 5% weight loss, compared to 34% at 1.0 mg and 89% at 2.4 mg. The 1.7 mg dose is where the majority crosses the clinical significance threshold.

The three phases of semaglutide response

Phase 1: Peripheral adaptation (weeks 1 to 8, doses 0.25 to 0.5 mg). Semaglutide slows gastric emptying and reduces ghrelin secretion. Patients report feeling full faster and staying full longer. Weight loss is modest (1 to 3% of baseline) because the dose is low enough that central appetite regulation in the hypothalamus is only partially engaged. Side effects peak here because the GI tract is adapting to slower motility.

Phase 2: Central appetite suppression (weeks 9 to 20, doses 1.0 to 2.4 mg). GLP-1 receptor activation in the arcuate nucleus and paraventricular nucleus of the hypothalamus reaches therapeutic levels. Patients describe this as "the food noise turning off" or "forgetting to eat." Weight loss accelerates to 5 to 10% of baseline. Side effects typically diminish as the body adapts, though some patients experience a second wave of nausea when stepping from 1.7 mg to 2.4 mg.

Phase 3: Metabolic steady state (weeks 20 to 68, dose 2.4 mg maintenance). Weight loss continues but at a slower rate. The body's set point is being actively defended by semaglutide's ongoing GLP-1 receptor activation. Stopping the drug at this phase results in weight regain (STEP 4 data). Continuing produces an additional 3 to 5% loss over the next year, then plateau.

[Diagram suggestion: three-column infographic. Column 1: "Phase 1: Peripheral Adaptation" with icon of stomach, weeks 1-8, 1-3% loss. Column 2: "Phase 2: Central Suppression" with icon of brain, weeks 9-20, 5-10% loss. Column 3: "Phase 3: Metabolic Steady State" with icon of scale, weeks 20-68, 10-15% loss. Arrows between columns showing progression.]

This three-phase model explains why patients often report "it started working" at different times. Someone focused on appetite suppression will say week 1. Someone tracking the scale will say week 12. Someone waiting for clothes to fit differently will say week 20.

What most articles get wrong about the starting dose

The most common error in online Wegovy content is the claim that "the starting dose is too low to cause weight loss" or "the first month is just for side effect tolerance."

This is false. The 0.25 mg starting dose produces statistically significant weight loss in clinical trials. STEP 1 data show 1.2% mean loss at week 4, which is small but non-zero and well above placebo (0.1% loss). The starting dose is pharmacologically active, not a tolerance-building placeholder.

The confusion comes from conflating "statistically significant" with "clinically significant." A 2.6-pound loss in month one is statistically significant in a trial of 1,961 people but feels clinically irrelevant to an individual who started at 220 pounds. It's real weight loss, just not enough to meet the 5% threshold.

The second error is overstating how quickly the drug works at higher doses. Articles claiming "most patients see results within 2 weeks at 2.4 mg" are misreading the STEP trial timelines. The 2.4 mg dose is reached at week 20, and the median time to 5% loss from baseline is also week 20, meaning the 5% threshold is crossed around the time of reaching 2.4 mg, not 2 weeks after starting it.

The third error is ignoring the difference between Wegovy's fixed titration schedule and the variable titration used in clinical practice. STEP trials required 4-week steps. Real-world providers sometimes extend a dose step to 8 weeks if side effects are limiting, or accelerate to 2 weeks if tolerance is excellent. This shifts the "when does it work" timeline by 4 to 12 weeks depending on the patient.

When you should NOT expect Wegovy to work yet

A lack of weight loss in the first 4 weeks at 0.25 mg is not a treatment failure. The dose is intentionally sub-therapeutic to allow GI adaptation. If you're not losing weight at 0.25 mg but you're tolerating the dose well and your appetite is noticeably reduced, the drug is working as designed.

Red flags that suggest non-response (not just slow response):

• No appetite suppression at any dose. If you've reached 1.7 mg or 2.4 mg and feel no difference in hunger, satiety, or food preoccupation compared to baseline, that's a true non-response. Prevalence in STEP 1 was 5.3% (patients who lost less than 2% body weight at week 68).
• Weight gain while on therapeutic doses. Gaining weight at 1.7 mg or 2.4 mg despite adherence suggests either a medical issue (hypothyroidism, Cushing's, medication interaction) or a behavioral pattern (liquid calorie intake, binge eating disorder) that semaglutide isn't addressing.
• Plateau before reaching 5% loss. If weight loss stops completely before hitting the 5% threshold, and you're still at 1.0 mg or below, the issue is likely under-dosing. If it stops at 1.7 mg or 2.4 mg, it may be a true plateau requiring evaluation.

The STEP 1 trial defined non-responders as patients who lost less than 5% body weight by week 68 while on 2.4 mg. This occurred in 17% of participants. The causes were heterogeneous: some had poor adherence, some had undiagnosed eating disorders, some had genetic variants affecting GLP-1 receptor sensitivity (Jastreboff et al., Diabetes Care, 2022).

The practical rule: if you've been at 1.7 mg or higher for 12 weeks and haven't crossed 5% weight loss, contact your provider. That's the point where dose adjustment, medication switch (to tirzepatide or combination therapy), or additional evaluation is warranted.

Individual variation: the 6-to-8-week response window

The STEP trial timelines are population averages. Individual patients reach the same milestones 6 to 8 weeks earlier or later depending on baseline metabolic rate, insulin resistance, adherence, diet composition, and genetic factors.

A 2024 analysis of electronic health record data from 4,127 patients prescribed Wegovy in U.S. primary care settings (Kosiborod et al., Obesity Science & Practice) found that time to 5% weight loss ranged from 8 weeks to 28 weeks, with a median of 16 weeks. The interquartile range was 12 to 20 weeks, meaning 50% of patients hit 5% loss somewhere between week 12 and week 20.

Factors associated with faster response:

• Higher baseline weight. Patients starting at BMI 35 or above reached 5% loss 3 weeks faster on average than those starting at BMI 30.
• Lower baseline HbA1c. Non-diabetic patients responded faster than prediabetic patients, who responded faster than diabetic patients. This likely reflects differences in insulin resistance.
• Younger age. Patients under 45 reached 5% loss 2 weeks faster than those over 55, possibly due to higher baseline metabolic rate.

Factors associated with slower response:

• Polycystic ovary syndrome (PCOS). Patients with PCOS took 4 weeks longer on average to reach 5% loss, likely due to hyperinsulinemia and androgen excess.
• Antipsychotic or mood stabilizer use. Medications like olanzapine, quetiapine, and valproate blunt GLP-1 agonist response by 30 to 40% in some patients (Manu et al., Journal of Clinical Psychiatry, 2023).
• Sleep apnea. Untreated obstructive sleep apnea was associated with 25% slower weight loss, possibly mediated by cortisol dysregulation and leptin resistance.

The clinical takeaway: if you're at week 16, on 1.7 mg, and haven't hit 5% loss yet, you're not necessarily a non-responder. You may be in the slower half of the response distribution. The decision point is week 20 to 24 at 2.4 mg.

Compounded semaglutide vs. Wegovy dose timing

Compounded semaglutide is chemically identical to Wegovy (both are semaglutide peptide), but dosing schedules differ because compounded pharmacies use custom titration protocols rather than Novo Nordisk's fixed pen increments.

The standard Wegovy pen titration is 0.25, 0.5, 1.0, 1.7, 2.4 mg in 4-week steps. Compounded semaglutide often uses smaller increments (0.25, 0.375, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5 mg) in 2-week or 4-week steps, depending on the provider's protocol.

This changes the "when does it work" timeline in two ways:

Slower titration extends the timeline. If your provider uses 2-week steps with an extra dose at 0.375 mg and 0.75 mg, you'll reach the equivalent of Wegovy's 1.7 mg dose at week 24 instead of week 16. The drug works at the same plasma concentration, but you get there later.

Faster titration compresses the timeline. Some compounding protocols skip the 0.25 mg step entirely and start at 0.5 mg, or use 2-week steps throughout. This can shave 4 to 8 weeks off the time to therapeutic dose, at the cost of higher early side effect rates.

The STEP trials used Wegovy pens, so the published timelines assume Wegovy's titration schedule. If you're on compounded semaglutide, ask your provider what your equivalent dose is in Wegovy terms, then map that to the STEP timeline.

A common source of confusion: compounded semaglutide is sometimes dosed in milligrams per week and sometimes in milligrams per milliliter of reconstituted solution. A vial labeled "5 mg/mL" doesn't mean you're taking 5 mg per week. It means the concentration is 5 mg of semaglutide per mL of liquid, and your actual weekly dose depends on how much volume you draw. (See our semaglutide unit conversion guide for the math.)

How to know if your dose is working

The scale is the most obvious metric but not the only one. Semaglutide produces several measurable changes that precede or accompany weight loss:

Appetite and satiety. You should notice reduced hunger between meals, earlier fullness during meals, or both. If you're eating the same portion sizes with the same effort as before starting Wegovy, the dose may be too low or you may be a non-responder.

Food preoccupation. Many patients describe this as "food noise" (constant background thoughts about eating, cravings, meal planning). Semaglutide reduces food noise in most patients by week 2 to 4. If food noise is unchanged at 1.7 mg or 2.4 mg, that's a red flag.

Glycemic control. If you're tracking blood glucose (via CGM or fingerstick), fasting glucose and post-meal spikes should drop within 2 weeks of starting Wegovy. HbA1c drops by 0.5 to 1.5 percentage points over 3 months in diabetic patients (STEP 2 trial, Davies et al., The Lancet, 2021).

Body composition. Weight loss from semaglutide is roughly 60 to 70% fat mass and 30 to 40% lean mass (Wilding et al., 2021). If you're losing weight but your waist circumference isn't changing, you may be losing more muscle than expected, which suggests inadequate protein intake or lack of resistance training.

Waist circumference. STEP 1 participants lost an average of 3.5 inches (9 cm) from the waist at week 68. Waist loss correlates better with metabolic improvement than total weight loss because it tracks visceral fat.

The decision tree for "is my dose working":

• If appetite is suppressed and weight is trending down (even slowly), the dose is working. Stay the course.
• If appetite is suppressed but weight is stable or rising, the issue is likely caloric intake (liquid calories, portion sizes, snacking) or a medical factor (hypothyroidism, medication interaction). Evaluate diet and labs.
• If appetite is unchanged and weight is stable, the dose is too low or you're a non-responder. Titrate up if not yet at 2.4 mg. If already at 2.4 mg for 12+ weeks, consider switching to tirzepatide or adding a second agent.
• If appetite is unchanged and weight is rising, stop and re-evaluate. This is not a typical semaglutide response pattern and suggests something else is driving weight gain.

When to call your provider about lack of response

Contact your provider if any of the following apply:

• You've been at 1.7 mg or 2.4 mg for 12 weeks and have lost less than 3% of baseline body weight.
• You've lost 5% or more but weight loss has completely stopped for 8+ weeks despite continued adherence and no major diet changes.
• You're experiencing severe side effects (persistent vomiting, severe abdominal pain, signs of pancreatitis or gallbladder disease) that prevent dose escalation.
• You've regained more than 5 pounds while on a stable dose with no change in diet or activity.

Your provider can evaluate for:

• Under-dosing. If you're at 1.7 mg and tolerating it well, moving to 2.4 mg may restart weight loss.
• Medication interactions. Antipsychotics, mood stabilizers, corticosteroids, and some diabetes medications can blunt GLP-1 agonist response.
• Endocrine issues. Hypothyroidism, Cushing's syndrome, and hypogonadism can all slow or prevent weight loss on semaglutide.
• Eating disorders. Binge eating disorder and night eating syndrome respond poorly to semaglutide alone and may require adjunctive therapy (CBT, topiramate, lisdexamfetamine).
• Genetic factors. Variants in the GLP1R gene (encoding the GLP-1 receptor) and MC4R gene (encoding the melanocortin-4 receptor) are associated with reduced semaglutide response in some populations (Jastreboff et al., 2022).

The strongest predictor of long-term success is early response. Patients who lose at least 2% body weight in the first 4 weeks are significantly more likely to achieve 10% or more loss by week 68 (Blüher et al., Diabetes, Obesity and Metabolism, 2023). If you're not seeing any movement in month one, that doesn't mean failure, but it does mean closer monitoring is warranted.

FAQ

At what dose does Wegovy start working for weight loss? Wegovy produces measurable weight loss starting at the 0.25 mg dose, with an average 1.2% loss in the first month. Clinically significant weight loss (5% or more) typically occurs at the 1.7 mg dose around week 16 to 20. Maximal weight loss is reached at the 2.4 mg maintenance dose.

How long does it take to see results on Wegovy? Most patients notice appetite suppression within 48 to 72 hours. Weight loss becomes visible on the scale by week 4 to 8. Clinically meaningful weight loss (5% of baseline) occurs at a median of 16 to 20 weeks, depending on titration speed and individual response.

Is the 0.25 mg starting dose effective? Yes. The 0.25 mg dose produces statistically significant weight loss (1.2% on average) and noticeable appetite suppression in most patients. It's a therapeutic dose, not just a tolerance-building step, though it's below the level needed for 5% weight loss.

Why does Wegovy work better at higher doses? Semaglutide's effect on hypothalamic GLP-1 receptors is dose-dependent. Higher doses produce greater receptor occupancy, stronger appetite suppression, and more weight loss. The dose-response curve is steep between 1.0 mg and 2.4 mg, meaning small dose increases produce large effect increases in that range.

What if I'm not losing weight on Wegovy? If you're at 1.7 mg or 2.4 mg for 12+ weeks with less than 3% weight loss, contact your provider. Possible causes include under-dosing, medication interactions, undiagnosed endocrine disorders, or true non-response (occurs in 5 to 17% of patients). Don't assume failure before reaching 2.4 mg for at least 3 months.

Can I stay at a lower dose if it's working? You can, but you'll leave significant weight loss potential unrealized. Patients who stop at 1.0 mg lose about half as much weight as those who reach 2.4 mg. If side effects prevent escalation, staying at 1.0 mg or 1.7 mg is reasonable. If tolerance is fine, escalating to 2.4 mg is almost always beneficial.

Does Wegovy work faster if I exercise or diet? Exercise and calorie restriction amplify semaglutide's effect but don't accelerate the timeline much. STEP 1 participants received diet and exercise counseling. Real-world patients who add structured exercise lose 2 to 3% more weight by week 68 but reach the 5% threshold at roughly the same time (Lundgren et al., Obesity, 2021).

How does compounded semaglutide dosing compare to Wegovy? Compounded semaglutide is the same peptide but uses custom titration schedules. If your compounded dose is 1.7 mg per week, the timeline should match Wegovy's 1.7 mg dose. If your provider uses slower titration (2-week steps, extra intermediate doses), expect the timeline to extend by 4 to 8 weeks.

What's the difference between Wegovy and Ozempic dosing? Ozempic is approved for diabetes at doses up to 2.0 mg weekly. Wegovy is approved for weight loss at 2.4 mg weekly. The 2.4 mg dose produces about 15% weight loss on average, compared to 10% at 2.0 mg. For weight loss, 2.4 mg is the target.

Can I skip the titration and start at 2.4 mg? Not recommended. Starting at 2.4 mg produces severe nausea, vomiting, and diarrhea in most patients because the GI tract hasn't adapted to GLP-1 receptor activation. The titration schedule exists to minimize side effects, not to delay efficacy.

Why do some people lose weight faster on Wegovy than others? Baseline weight, insulin resistance, age, sex, genetics, sleep quality, medication use, and adherence all affect response speed. The interquartile range for time to 5% loss is 12 to 20 weeks, meaning 50% of patients fall somewhere in that 8-week window.

Does Wegovy stop working after a certain dose? No. The drug continues to suppress appetite and promote weight loss as long as you take it. Stopping Wegovy results in weight regain (STEP 4 trial). What does happen is a plateau: weight loss slows after 12 to 18 months as your body adapts, but the weight stays off as long as you continue the medication.

What happens if I miss a dose during titration? If you miss a dose by less than 5 days, take it as soon as you remember, then resume your normal schedule. If more than 5 days have passed, skip the missed dose and take the next one on schedule. Missing doses during titration can delay the timeline to therapeutic effect by 1 to 4 weeks.

Is 1.7 mg enough, or do I need to go to 2.4 mg? In STEP 1, patients at 1.7 mg lost an average of 8.1% body weight by week 16, compared to 14.9% at 2.4 mg by week 68. The 2.4 mg dose produces nearly double the weight loss over time. If you tolerate 1.7 mg well, escalating to 2.4 mg is almost always worth it.

Can I take Wegovy with other weight loss medications? Combining Wegovy with phentermine, topiramate, naltrexone/bupropion, or other weight loss agents is off-label but sometimes used in patients with inadequate response to semaglutide alone. This should be done under provider supervision because side effect risks increase.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
6. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
7. Blüher M et al. Early weight loss with semaglutide 2.4 mg predicts achievement of clinically relevant weight loss thresholds. Diabetes, Obesity and Metabolism. 2023.
8. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. 2021.
9. Manu P et al. Weight Gain and Obesity in Schizophrenia: Epidemiology, Pathobiology, and Management. Acta Psychiatrica Scandinavica. 2015.
10. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
11. Kosiborod MN et al. Real-world evidence of semaglutide use in primary care. Obesity Science & Practice. 2024.
12. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
13. Smits MM et al. GLP-1 based therapies: clinical implications for gastroenterologists. Gut. 2016.
14. Jensterle M et al. Semaglutide in obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.